Table 3.
Combination Therapy in PAH
| Combination | 6MWD Improvement* (m) | Other Evaluations | ||
|---|---|---|---|---|
| Bosentan _ inhaled iloprost STEP trial (n _ 67) |
Peak†: 26 m (p _ 0.05) Trough: no difference |
Improved functional class, time to clinical worsening, post-inhalation hemodynamics (p _ 0.05) | ||
| COMBI trial (n _ 40): unblinded randomized | No difference | No difference functional class, time to clinical worsening | ||
| IV epoprostenol _ oral therapy BREATHE-2 trial (n _33) |
No difference | Trend toward greater improvement in PVR (p _ 0.08) | ||
| PACES trial (n _ 267) epoprostenol _ sildenafil |
26 m (p _ 0.05) | Improved hemodynamics, time to clinical worsening (p _ 0.05) | ||
| Oral therapy _ inhaled treprostinil TRIUMPH-1 trial (n _ 235) |
Walk improvement reported as positive (press release); results expected 2008 | |||